Revalsmen of marijuana as an indefinite period of postponed Schedule III – Bizwest

Marijuana is currently classified together with Heroin, LSD and Ecstasy as a medication for Schedule I as part of the Federal Law for Controlled Substances (ACT). In 2024, the Drug Enforcement Administration (DEA) asked to transfer marijuana to Appendix III according to Appendix I. Schedule III medication are those with moderate to low potential for physical and psychological dependency. In this article, DEA's request is discussed to re -classify marijuana as medication for Schedule III, why the matters are re -planning why the request was postponed and what happens next.

During his term in office, President Biden asked the Ministry of Health and Human Services (HHS) to initiate the administrative procedure to check how marijuana is planned according to the federal law. HHS, as the president asked, and found that marijuana in Schedule I and II has less potential for abuse than the drugs or other substances and that the abuse of marijuana can lead to moderate or low physical dependence or a high psychological dependency that corresponds to classification as Schedule III medicinal products. The DEA then published a message about the proposed regulation and asked to transfer marijuana from Annex I to Annex III.

When approved, the rescheduling can influence the business world in different ways. As a drug for Schedule III, marijuana would be recognized by the federal government for the first time as medical purposes and a little potential for abuse as a medication for Schedule I or II. In addition, the rescheduling would enable doctors to prescribe marijuana according to the federal law that would open up the door for financing and research and encourage pharmaceutical companies to go on the market to create and sell new cannabis products. Medical marijuana operators can also re -classify tax benefits according to Appendix III. However, it is important to note that a new classification would not change the criminal law that applies to marijuana users or operators for leisure workers.

The DEA's rescheduling request was criticized. The DEA planned a hearing, in order to obtain factual evidence and expert opinions on the rescheduling, but a group of participants in Pro-Resplaning leaned the role of the DEA in the hearing in order to have disqualified the DEA based on alleged conflicts of interest and ex-party communication with the opposition. An administrative judge (ALJ) rejected this application and asked the participants for the kidnapping to ask the ALJ, to rethink or allow the decision to make an appeal. The ALJ rejected the application for review, but made the application to submit an appeal. The ALJ then canceled the hearing, which began on January 21, 2025 until the complaint was approved.

As a result, the complaint must be decided before the rescheduling application can be continued. It is also not known which attitude the Trump government will take this problem.

If you have any questions about the proposed rescheduling, contact the BHGR cannabis group today.

This article is only informative. The presentation or use of this information in no way forms a relationship between the BHGR and the website user. While the information on this website concerns legal questions, this is not intended as legal advice and is not a substitute for special advice from your own legal advisor.